Building an Early Drug Developability Assessment System for Small Molecule Innovations Based on Precise ADME/Tox Characterization
Epigenic
Gene Editing Technology Developer
Chinese Biopharmaceutical Association - USA, China Branch (CBA-China)Always committed to building a bridge connecting China and the U.S., integrating Eastern and Western academia and industry. Based on the global wave of biopharmaceutical innovation, focusing on industry pain points and future trends, we willMay 8-10InWuxi International Convention CenterHost2026 CBA-China Annual Conference in China。The conference was themed “Breaking the Deadlock, Symbiosis for the Future —— Addressing Global Changes, Building a New Ecosystem for Drug Innovation and Accessibility" as the theme, bringing together 260+ authoritative guests from home and abroad, 4000+ industry elites, and meticulously crafting 13 parallel forums, coveringEarly Development、Clinical Translation、Global Registration、CGT、ADC、AI Drug Discovery、Investment and Financing BDCore tracks of the entire industrial chain. From frontier technology analysis to industry policy interpretation, from project对接to capital cooperation, the complete agenda comprehensively presents the global pharmaceutical innovation ecosystem, offering industry peers a high-standard, full-dimensional, and deeply insightful annual intellectual feast.
Yi Jie Li Ke (Epigenic) Translational Medicine Director Cheng YifanWill attend this conference and on the afternoon of May 10th "From Target to IND: Small Molecule Innovation and R&D Decision-MakingForum Presentation of Keynote Speech:Construction of an Early Drug-Likeness Evaluation System for Small-Molecule Innovative Drugs Based on Precise ADME/Tox Characterization。
Yifan Cheng, Master of Toxicology and Ph.D. in Pharmaceutics (in progress), has over 15 years of hands-on experience across the entire pharmaceutical R&D chain. He holds authoritative qualifications such as Chinese Toxicologist, American DABT, AIGC Senior Trainer, and GCP, and is proficient in pharmacokinetic modeling, data statistics, and non-clinical safety evaluation. He has led the successful IND approval of 8 Class 1 new drugs and multiple improved new drugs, advancing several molecules to the NDA stage, covering core areas such as autoimmune diseases, metabolism, hepatitis B, and oncology. He successfully promoted the first epigenetic regulation tool in China to receive FDA IND approval and was deeply involved in cross-border BD cooperation and large-scale financing support. Skilled in full-cycle R&D management from PCC to NDA, CRO control, and clinical translation, he integrates top professional technology with AI-enabled advantages and is a senior expert in pharmaceutical translational medicine and new drug applications.
Conference Name:2026CBA-China Annual Conference in China
Hosted by:Chinese Biopharmaceutical Association - USA, China Branch (CBA-China)
Organizer:BioValley
Conference Time:May 8-10, 2026 (Friday-Sunday)
Venue:Wuxi International Convention Center
Conference Scale:4,000 people
Participants:Biopharmaceutical companies, project management and senior company executives, registration and overseas personnel, research institutes and hospitals, investment and consulting firms, factory construction and clean equipment.
Scan to Register
*From now until April 30, 2026, registration is free;Starting from May 1st, the conference registration fee will be 100 yuan per person;
*Forward this post to your WeChat Moments, collect 18 likes, and redeem a meal voucher or a精美礼品on site. Limited quantity, first come, first served.
Conference Agenda Preview
CBA-China 2026
Agenda Unveiled with a Bang
CBA-China 2026
The specific agenda is subject to change; please refer to the final announcement...
Limited-time Free Registration Channel
(From now until April 30)
Scan the code to enter the conference group chat
(Note CBA2026)
| Business Cooperation
Stephen Sun
T: 15966587556
E: sunhx@biovalleyclub.com
| Academic Report
Seven Lu
T: 13641798663
E: tianyi.lu@biovalleyclub.com
| Media Cooperation/Event Participation Inquiry
Abby Jiang
T: 18217659261
E: xiaolang.jiang@biovalleyclub.com
About CBA
Chinese American Biopharmaceutical Society(Chinese Biopharmaceutical Association-USA, abbreviated as CBA) was founded in 1995 and is the largest Chinese-American professional association in the biopharmaceutical industry in the United States.
The primary mission of CBA is to serve as a bridge for cooperation between the United States and China in the biopharmaceutical field, promote comprehensive exchanges among professionals in the pharmaceutical industry of both countries, and provide a favorable environment for the development and collaboration of biopharmaceutical companies and research institutions.
CBA members come from a diverse range of backgrounds, including emerging technology companies in the U.S. and China, multinational pharmaceutical corporations, universities, research institutions, government medical review departments, various support funds for research or industrial development, as well as professional organizations specializing in law and intellectual property. Over 80% of CBA members hold a Ph.D.
CBA has a good reputation internationally, with members遍布世界各地, including China, the United States, Europe, Canada, Australia, Singapore, and Japan. Currently, there are more than 10,000 individual members and over 1,000 corporate members.
CBA has a close relationship with the U.S. Food and Drug Administration (FDA). Many of its presidents have worked at the FDA and are familiar with international biopharmaceutical registration strategies and other regulations. CBA also maintains strong ties with the University of Maryland, Johns Hopkins University, and its School of Medicine. Additionally, Jiangsu Province and Maryland State share a sister-state relationship.
Thanks to the support of the following cooperative media
Click "Read the Original Text", sign up now~